Galectin Therapeutics (GALT) Preferred Shares (2010 - 2026)
Galectin Therapeutics (GALT) recorded quarterly Preferred Shares of $480000.0 in Q1 2026, down 2.04% quarter-over-quarter from $490000.0 in Q4 2025, and down 4.0% on a YoY basis from $500000.0 in Q1 2025.
Galectin Therapeutics (GALT) Preferred Shares (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Preferred Shares history runs 17 years deep, the most recent figure standing at $480000.0 for Q1 2026.
- In Q1 2026, Preferred Shares fell 4.0% year-over-year to $480000.0; the TTM figure through Mar 2026 stood at $480000.0 (down 4.0% YoY), while the FY2025 annual figure was $490000.0, down 2.0% from the prior year.
- Preferred Shares was $480000.0 for Q1 2026 at Galectin Therapeutics, down from $490000.0 in the prior quarter.
- In the past five years, Preferred Shares ranged from a high of $527000.0 in Q1 2022 to a low of $480000.0 in Q1 2026.
- Historically, Preferred Shares has averaged $502176.5 across 5 years, with a median of $500000.0 in 2023.
- The sharpest annual moves came in 2022 and 2026: Preferred Shares changed 0.0% in 2022, then fell 4.0% in 2026.
- A 5-year view of Preferred Shares shows it stood at $510000.0 in 2022, then declined by 1.96% to $500000.0 in 2023, then changed by 0.0% to $500000.0 in 2024, then dropped by 2.0% to $490000.0 in 2025, then retreated by 2.04% to $480000.0 in 2026.
- The last three Preferred Shares figures came in at $480000.0 (Q1 2026), $490000.0 (Q4 2025), and $490000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Galectin Therapeutics | 185.83 Mn | 171.73 Mn | - | 480,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 480,000.00 |
| Dec 31, 2025 | 490,000.00 |
| Sep 30, 2025 | 490,000.00 |
| Jun 30, 2025 | 490,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Dec 31, 2023 | 500,000.00 |
| Sep 30, 2023 | 510,000.00 |
| Jun 30, 2023 | 510,000.00 |
| Mar 31, 2023 | 510,000.00 |
| Dec 31, 2022 | 510,000.00 |
| Sep 30, 2022 | 510,000.00 |
| Jun 30, 2022 | 510,000.00 |
| Mar 31, 2022 | 527,000.00 |
| Dec 31, 2021 | 527,000.00 |
| Sep 30, 2021 | 527,000.00 |
| Jun 30, 2021 | 527,000.00 |